Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aviptadil for COVID-19 ARDS (ACTIV-3b/TESICO)
NCT06729606Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aviptadil in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2021; status: completed.
02
Drugs
aviptadil
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06729606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729606.